Literature DB >> 33086278

Elevated 68Ga-FAPI Accumulation in a Recurrent Angiomyolipoma.

Chunxia Qin1, Yongkang Gai, Qingyao Liu, Fuqiang Shao, Xiaoli Lan.   

Abstract

Ga-FAPI (Ga-labeled fibroblast activation protein inhibitor) PET imaging has been recently introduced for the diagnosis and staging in various malignant tumors. However, the reports about the utility of FAPI imaging in benign tumor are relatively rare. Here we report a case of pathologically proven recurrent angiomyolipoma in the left retroperitoneal area with low F-FDG uptake but diffuse heterogeneous intense Ga-FAPI uptake together with suspected lung metastases in a 53-year-old woman. Our case illustrates FAPI imaging could be helpful not only for detecting various malignant tumors but also for benign tumor like this case due to fibrotic activity in the disease.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33086278     DOI: 10.1097/RLU.0000000000003345

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  3 in total

Review 1.  Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

Authors:  Mengting Li; Muhsin H Younis; Yongxue Zhang; Weibo Cai; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-31       Impact factor: 10.057

2.  Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?

Authors:  Hessamoddin Roustaei; Zahra Kiamanesh; Emran Askari; Ramin Sadeghi; Kamran Aryana; Giorgio Treglia
Journal:  Contrast Media Mol Imaging       Date:  2022-02-22       Impact factor: 3.161

3.  Increased uptake of 68Ga-DOTA-FAPI-04 in bones and joints: metastases and beyond.

Authors:  Chunxia Qin; Yangmeihui Song; Xi Liu; Yongkang Gai; Qingyao Liu; Weiwei Ruan; Fang Liu; Fan Hu; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-09       Impact factor: 10.057

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.